The Life Sciences Report
Other Streetwise Reports
The Gold Report The Energy Report The Life Sciences Report The Metals ReportMore Experts
"NEO is a small but focused diagnostic company with numerous competitive advantages." (4/4/13) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey More >
"ATHX has one of the best manufacturing processes in allogeneic cell therapy I've ever seen." (3/14/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >
Sector Experts
Elemer Piros
Elemer Piros joined Burrill & Co. from Rodman & Renshaw, where he served as a managing director and senior biotechnology analyst since 2002. He has ranked among the top analysts in various surveys, including ranking as the top biotechnology analyst by the Wall Street Journal in 2006 and by the Financial Times in 2010, based on stock portfolio performance. Prior to that, he served as a senior biotechnology analyst at Ladenburg Thalmann, and as a biotechnology research analyst with Spear, Leeds & Kellogg/Goldman Sachs. Before serving as an analyst, Piros spent eight years conducting research in biophysics, biochemistry and molecular biology at Cornell University and the University of California, Los Angeles. He holds a doctorate in neurosciences from UCLA, a bachelor's degree in biology from UCLA, and a bachelor's degree in mathematics and technology from Eotvos Lorand University in Budapest.
Recent Interviews
Do You Have the Guts to Take On Cutting-Edge Biotech Like This VC? (12/13/12) With the odds stacked against a drug entering clinical trials, investors need to be assured that the upside will be momentous when success does come. Burrill & Co. Managing Director Elemer Piros leverages science and the unmet needs of patients with his extensive knowledge of the capital markets to bring lower-risk, higher-return ideas to investors. In this interview with The Life Sciences Report, Piros explains his investment thesis and zeroes in on best bets.
Recent Quotes
"PVCT's phase 2 trial results for PV-10 are very encouraging." (6/26/12) Provectus Pharmaceuticals Inc. - Elemer Piros, Burrill and Company More >
"ONCS announced positive results in its single-arm phase 4 trial." (4/20/12) OncoSec Medical Inc. - Elemer Piros, Rodman & Renshaw More >
"ONCS' DNA IL-12 is one of the best characterized and potent anti-tumor cytokines." (4/11/12) OncoSec Medical Inc. - Elemer Piros, Rodman & Renshaw More >
"We maintain our Market Outperform rating for PVCT." (3/26/12) Provectus Pharmaceuticals Inc. - Elemer Piros, Rodman & Renshaw More >
Notable Quotes
"I think GALE has a good shot on its phase 3 NeuVax trial." (5/23/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Echo He More >
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >